Ronawk
Develops 3D bioprinted hydrogel substrates (Bio-Blocks) for tissue-mimetic cell culture, eliminating subculture to accelerate research and therapeutic development.
- CEO / Founder
- A.J. Mellott
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $7.9M
- Latest Round
- Series A
- Key Investors
- Manhattan Venture Partners; MassChallenge; Digital Sandbox KC
Technology & Products
Key Products
Bio-Blocks (T-Blocks, X-Blocks, E-Blocks); Bio-OS platform; 3D printing services; Imaging services
Technological Advantage
Patented 3D porous hydrogel design (verified in publications) enables 95% cell retrieval vs. 70% industry standard; defensible via trade secrets and pending patents.
Differentiation
Value Proposition
Reduces cell culture time by eliminating subculture, increasing biological yield by 30-50%, lowering contamination risk by 60%, and cutting labor costs by 40% for scalable therapeutic production.
How They Differentiate
3x higher cell yield retention (95% vs. 70% for Organovo) and eliminates subculture vs. competitors requiring frequent passaging; 40% lower cost-per-cell for large-scale production.
Market & Competition
Target Customers
Biotech firms, CDMOs, CROs, biopharma companies, academic labs, regenerative medicine partners
Industry Verticals
Biotechnology; Regenerative Medicine; Pharmaceuticals; Life Sciences
Competitors
Organovo; CELLINK; Allevi
Growth & Milestones
Growth Metrics
Revenue grew 200% YoY; expanded team from 15 to 20 employees in 2023; secured partnerships with 10+ biotech firms.
Major Milestones
Founded in 2019; Launched Bio-Block Universe in 2021; Closed $1.5M seed round in 2023; Secured $6M Series A in May 2023; Partnered with B9Creations in June 2024
Notable Customers
University of Kansas Medical Center, Stowers Institute for Medical Research, Johnson & Johnson (via JLABS @KC incubator partnership), Organovo Holdings (collaborative R&D)